Gossamer Bio (NASDAQ:GOSS) Coverage Initiated by Analysts at Barclays

Barclays started coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report sent to investors on Tuesday, Marketbeat.com reports. The firm issued an overweight rating and a $9.00 price target on the stock.

GOSS has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Gossamer Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.60.

Gossamer Bio Stock Down 2.2%

Shares of NASDAQ:GOSS traded down $0.06 during trading on Tuesday, reaching $2.50. The stock had a trading volume of 527,711 shares, compared to its average volume of 4,488,930. The stock has a market cap of $577.49 million, a P/E ratio of -3.60 and a beta of 1.92. The business has a fifty day moving average price of $3.07 and a 200-day moving average price of $2.62. Gossamer Bio has a fifty-two week low of $0.76 and a fifty-two week high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. As a group, equities analysts forecast that Gossamer Bio will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Gossamer Bio during the 4th quarter worth $148,000. Merit Financial Group LLC grew its stake in shares of Gossamer Bio by 15.2% in the fourth quarter. Merit Financial Group LLC now owns 155,178 shares of the company’s stock valued at $481,000 after buying an additional 20,490 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Gossamer Bio during the 4th quarter valued at about $35,000. CWM LLC lifted its position in Gossamer Bio by 35.7% during the 4th quarter. CWM LLC now owns 33,957 shares of the company’s stock worth $105,000 after acquiring an additional 8,940 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in Gossamer Bio in the 4th quarter worth approximately $2,024,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.